RxDoctor Payments Data

Haley Zimmerman

Registered Nurse · Pasadena, MDNPI 1770276057

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Novo Nordisk at 39.8% of the total. 2025 is the largest year on record at $399, 5.3 times the $75 reported in 2023.

$614in general payments, 2019–2025

Across 30 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$245
  • GSK$132
  • AbbVie$70
  • Astellas Pharma US Inc$55
  • Lilly USA, LLC$53
  • Exact Sciences$36
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$614100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk13$245
GSK5$132
AbbVie3$70
Astellas Pharma US Inc3$55
Lilly USA, LLC3$53
Exact Sciences2$36
Watermark Medical, Inc.1$23

How this compares

$614 in reported general payments places this provider in the 85th percentile of 89 registered nurse providers in Maryland.

See all registered nurse providers in Maryland

Medicare billing

Part B allowed, 2024
$42,701
Medicare patients
140
Services billed
392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$38,557
OzempicSemaglutide15$17,297
EliquisApixaban17$16,444
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,191
Atorvastatin Calcium137$1,925
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,602
Albuterol Sulfate HfaAlbuterol Sulfate48$1,547
Rosuvastatin Calcium41$1,274
Gabapentin55$1,170
Bupropion XlBupropion Hcl33$1,086
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide17$944
Lisinopril97$691
Escitalopram Oxalate11$682
Amlodipine Besylate93$667
Pantoprazole Sodium49$657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$245$17,29715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 89 registered nurse providers in Maryland.

Other registered nurse in Pasadena

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →